The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia

被引:0
|
作者
H Nückel
M Switala
L Sellmann
P A Horn
J Dürig
U Dührsen
R Küppers
H Grosse-Wilde
V Rebmann
机构
[1] University Hospital Essen,Department of Haematology
[2] Institute of Transfusion Medicine,undefined
[3] University Hospital Essen,undefined
[4] Institute of Cell Biology (Cancer Research),undefined
[5] University Hospital Essen,undefined
[6] Institute of Immunology,undefined
[7] University Hospital Essen,undefined
来源
Leukemia | 2010年 / 24卷
关键词
NKG2D ligands; prognostic marker; CLL;
D O I
暂无
中图分类号
学科分类号
摘要
Soluble or membrane-anchored ligands of NKG2D and their receptor have a critical role in the elimination of tumor cells and disease progression. Plasma samples of 98 patients with B-cell chronic lymphocytic leukemia (CLL) were analyzed with specific ELISA systems for soluble major histocompatibility complex class I-related chains (sMICA and sMICB) and UL-16-binding proteins (ULBP1, 2, and 3). The flow cytometric analysis of MICA on CLL cells and natural killer group 2 member D (NKG2D) receptors on NK cells was performed after thawing of frozen peripheral blood lymphocytes of CLL patients (N=51). Levels of sMICA, sMICB, and sULBP2 were significantly increased (P<0.001) compared with 48 controls, whereas sULBP1 3 were not detectable in patients and controls. Levels of sMICA>990 pg/ml (P=0.014), sMICB>200 pg/ml (P=0.0001), and sULBP2>105 pg/ml (P<0.0001) were associated with poor treatment-free survival (TFS). Neither MICA nor NKG2D expression could be related to clinical parameters. In multivariate analysis Binet stage (P=0.002), sULBP2 (P=0.002) and ZAP-70 (P=0.002) were independent predictive factors for TFS. In patients with Binet stage A, sULBP2 levels>105 pg/ml were strongly associated (P=0.0025) with poor TFS. Our data show that soluble but not membrane-anchored NKG2D ligands or receptors are of prognostic significance in CLL. Moreover, sULBP2 seems to be useful to identify early-stage patients with risk of disease progression.
引用
收藏
页码:1152 / 1159
页数:7
相关论文
共 50 条
  • [31] Prognostic value of translocations in B-CELL chronic lymphocytic leukemia (B-CLL)
    Van den Neste, E.
    Robin, V.
    Maerevoet, M.
    Hagemeijer, A.
    Stul, M.
    Constantini, S.
    Robert, A.
    Ferrant, A.
    Michaux, L.
    ACTA CLINICA BELGICA, 2006, 61 (02) : 99 - 99
  • [32] The prognostic significance of surface dipeptidylpeptidase IV (CD26) expression in B-cell chronic lymphocytic leukemia
    Matuszak, Magdalena
    Lewandowski, Krzysztof
    Czyz, Anna
    Kiernicka-Parulska, Jolanta
    Przybylowicz-Chalecka, Anna
    Jarmuz-Szymczak, Malgorzata
    Lewandowska, Maria
    Komarnicki, Mieczyslaw
    LEUKEMIA RESEARCH, 2016, 47 : 166 - 171
  • [33] The prognostic significance of dipeptidyl peptidase IV (CD26) expression in B-cell chronic lymphocytic leukemia
    Abaza, Hala M. H.
    Eltawil, Ahmed E.
    Safwat, Nesma A.
    Elzeiny, Walaa S.
    EGYPTIAN JOURNAL OF HAEMATOLOGY, 2021, 46 (01): : 11 - 22
  • [34] Biologic complexities of prognostic markers in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma
    Soma, LA
    Craig, FE
    Melan, M
    Kant, JA
    Swerdlow, SH
    LABORATORY INVESTIGATION, 2005, 85 : 251A - 251A
  • [35] Biologic complexities of prognostic markers in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma
    Soma, LA
    Craig, FE
    Melan, MA
    Kant, KA
    Swerdlow, SH
    MODERN PATHOLOGY, 2005, 18 : 251A - 251A
  • [36] Biological and clinical significance of stereotyped B-cell receptors in chronic lymphocytic leukemia
    Rossi, Davide
    Gaidano, Gianluca
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (12): : 1992 - 1995
  • [37] Prognostic irrelevance of HLA-G in B-cell chronic lymphocytic leukemia
    Perez-Chacon, G.
    Rosado, S.
    Rebolleda, N.
    Losada-Fernandez, I.
    Vargas, J. A.
    Morado, M.
    Jorda, J.
    Perez-Aciego, P.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2009, 31 (03) : 327 - 337
  • [38] Definition and validation of novel prognostic markers in B-CELL chronic lymphocytic leukemia
    Kotaskova, J.
    Tichy, B.
    Malcikova, J.
    Kuhrova, V.
    Doubek, M.
    Brychtova, Y.
    Borsky, M.
    Dvorakova, D.
    Mayer, J.
    Pospisilova, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 390 - 390
  • [39] Alemtuzumab for B-cell chronic lymphocytic leukemia
    Robak, Tadeusz
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (07) : 1033 - 1051
  • [40] Rituximab in B-cell chronic lymphocytic leukemia
    Lin, TS
    Lucas, MS
    Byrd, JC
    SEMINARS IN ONCOLOGY, 2003, 30 (04) : 483 - 492